JPM24, Day 1: Regeneron's Eylea misses analyst estimates; Moderna touts $6.7B in '23 sales

Regeneron hopes its longer-lasting Eylea formulation, Eylea HD, can build on the success of the company's original blockbuster product. With $123 million in sales during Eylea HD's first quarter on the market, the eye med is showing early indicators of broad initial uptake, CEO Leonard Schleifer, M.D., Ph.D., said in a corporate update. But overall Q4 Eylea sales, at $1.46 billion, missed analyst expectations of $1.49 billion to $1.56 billion, according to Piper Sandler analyst Christopher Raymond.